Amicus Briefs

BIO submits amicus briefs on a variety of topics because of the strong interest and relevance to the biotechnology industry.

Featured Amicus Briefs
BIO FILES AMICUS BRIEF CHALLENGING FTC’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
BIO Files Amicus Brief in U.S. ex rel. Scutte v…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
BIO JOINS AMICUS BRIEF CHALLENGING COURT’S…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…
All Amicus Briefs
  • Show All
Search
Results
March 17, 2017
BIO Submits Brief of Amicus Curiae in Sandoz Inc. v. Amgen Inc. v. Sandoz Inc. (Supreme Court of the United States)  
March 8, 2017
BIO and AUTM Submit Brief of Amicus Curiae in TC Heartland LLC v. Kraft Food Group Brands LLC (Supreme Court of the United States)
February 23, 2017
BIO and Croplife International Submit Brief of Amicus Curiae in Impression Products Inc. v. Lexmark International Inc. (Supreme Court of the United States)
February 23, 2017
BIO Submits Brief of Amicus Curiae in Wi-Fi One, LLC v. Broadcom Corporation (U.S. Court of Appeals for the Federal Circuit)
February 9, 2017
BIO and PhRMA Submit Brief of Amicus Curiae In Re: Verinata Health Inc., Illumina, Inc. 
October 25, 2016
The Biotechnology Innovation Organization submitted a brief of amicus curiae supporting the appellant in the case In Re: Aqua Product, Inc. in the United States Court of Appeals for the Federal Circuit
March 3, 2016
Modern pharmaceutical and biotechnology products typically require lengthy, costly, and resource-intensive development periods before they reach the marketplace. BIO members devote many years and millions of dollars in direct …
March 2, 2016
The questions presented in this case implicate two of the foundational legal conclusions that have allowed the PTAB, even in a relatively short time, to cut a remarkable swath through the ranks of issued patents with barely a…
February 16, 2016
BIO as Amicus Curiae supporting en banc reconsideration in Prolitec, Inc. v. ScentAir Technologies, Inc. (US Court of Appeals for the Federal Circuit)   STATEMENT OF INTEREST OF AMICUS CURIAE The Biotechnology Innovation Organization (&ldquo…
February 16, 2016
Brief of Amicus Curiae Biotechnology Innovation Organization in Support of Plaintiffs-Appellees in Amgen Inc. v. Apotex Inc. (U.S. Court of Appeals for the Federal Circuit) INTEREST OF AMICUS CURIAE   The Biotechnology Innovation Organization (…